Biotechnology

Happiness Biotech Group Limited Announces Financial Results for the Six Months Ended September 30, 2019

NANPING, China, Jan. 17, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months endedSeptember 30, 2019. The financial results...

2020-01-17 21:00 2098

GenScript and Genopis Enter Into Strategic Partnership Agreement for Manufacture Service of GMP Plasmids

NANJING, China, Jan. 15, 2020 /PRNewswire/ -- On January 14, 2020, at San Francisco, USA, a global leading biotech company GenScript announced that it signed a strategic partnership agreement for the manufacturing service of GMP Plasmids with Genopis, Inc., a company that specializes in plasmid D...

2020-01-16 01:00 328

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully ...

2020-01-13 22:00 4507

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...

2020-01-09 17:10 720

Transcenta Holding Secures $100 Million Series B Plus Financing

HONG KONG and SUZHOU and HANGZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 millio...

2020-01-08 21:00 375

Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies

SUZHOU, China and SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed usingTruUCAR™ to treat relapsed or refr...

2020-01-07 22:00 264

Beta Lifescience Announces the Online Availability of Quality Immune Checkpoint Proteins for Scientific Discoveries

FIREFILED, N.J., Jan. 7, 2020 /PRNewswire/ -- Beta Lifescience, a world leading biotech company based in NJ, USA, announces that scientists in the field of cancer immunotherapy, immune checkpoint, targeted therapy, etc. now have access to the quality immune checkpoint protein products through the...

2020-01-07 21:10 255

Transcenta to Present at the 38th Annual J.P. Morgan Healthcare Conference

HONG KONG, SUZHOU, China and HANGZHOU, China, Jan. 6, 2020 /PRNewswire/ -- Transcenta Holding (Transcenta) today announced that Co-founder & CEO Dr. Xueming Qian will present at the 38th Annual J.P. Morgan Healthcare Conference onWednesday, January 15, 2020, at 14:30 PST in Golden Gate room at Wes...

2020-01-07 00:00 285

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

SHANGHAI, Jan. 3, 2020 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a global biopharmaceutical company based inChina and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced the dosing o...

2020-01-04 00:07 952

AgriTalk Integrates Biotechnology, Iot, Big Data Analysis, and Ai to Develop a Non-Toxic Agricultural Disease and Fertilizer Regulation System

TAIPEI, Jan. 3, 2020 /PRNewswire/ -- AgriTalk and other notable homegrown startups led by Taiwan Tech Arena (TTA) are now showcasing their innovative solutions at CES 2020. Dr. W...

2020-01-03 13:14 389

WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility

SHANGHAI, Jan. 2, 2020 /PRNewswire/ -- STA Pharmaceutical Co., Ltd.,  (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility inChangzhou, China. This signifi...

2020-01-03 08:10 425

Gracell to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

SHANGHAI and SUZHOU, China, Dec. 30, 2019 /PRNewswire/ -- Gracell Biotechnologies Co. Ltd., a clinical-stage immune cell therapy company, has announced it will present at leading healthcare conferences inSan Francisco, California at the beginning of January 2020. Gracell will present at the 38th ...

2019-12-30 23:09 558

GenScript and Selecxine Enter Into Strategic Cooperation Agreement

SEOUL, South Korea, Dec. 26, 2019 /PRNewswire/ -- On Dec. 23, 2019, at Seoul, South Korea, the CDMO segment of the world's leading biotech company GenScript announced that it signed a strategic collaboration agreement with Selecxine Inc., a Korean biotech company dedicated to novel therapeutics f...

2019-12-26 22:00 9397

Viva Biotech Awarded 'Top 10 Public Companies'

BEIJING, Dec. 24, 2019 /PRNewswire/ -- The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held inBeijing. Viva Biotech was invited to the Summit and awarded the 'Top 10 Public Companies 2019' with honor. Dr. David Xu, the Chief Business Officer of Viva Biotech, was ...

2019-12-24 18:18 671

China's Largest Plasmid and Virus Facility from GenScript was Put into Operation

ZHENJIANG, China, Dec. 20, 2019 /PRNewswire/ -- The CDMO segment of the world's leading biotech company GenScript announced that GenScript's plasmid and virus facility was put into operation onDecember 18, 2019. It is a milestone on the path to industrialization of the gene and cell therapy indus...

2019-12-20 22:00 11440

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry...

2019-12-20 10:19 317

TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure

NANJING, China, Dec. 16, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based inNanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for TT-00920, a novel ...

2019-12-17 08:00 338

Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS

TAIPEI and SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Senhwa Biosciences Inc. (TPEx: 6492), a clinical stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced positive results from its Phase 1 trial of CX-5461. C...

2019-12-13 04:00 968

Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies

SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...

2019-12-09 22:00 505

BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors

HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the 'company') today announced that the first patient was successfully dosed on December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001 program at NEXT ONCOLOGY inSan Antonio, Texas.

2019-12-09 21:00 411
12345 ... 97